Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2024 Apr;165(4):1020-1024.
doi: 10.1016/j.chest.2023.10.033. Epub 2023 Oct 31.

Stage at Diagnosis Following Delay to Interval Scans for Indeterminate Nodules in Lung Cancer Screening: An Observational Study Examining the Outcomes of CHEST Expert Panel Recommendations

Andrew W Creamer  1 , Carolyn Horst  1 , Jennifer L Dickson  1 , Sophie Tisi  1 , Helen Hall  1 , Priyam Verghese  1 , Ruth Prendecki  1 , Amyn Bhamani  1 , Chuen R Khaw  1 , John McCabe  1 , Tanita Limani  2 , Kylie Gyertson  2 , Anne-Marie Hacker  3 , J Teague  3 , L Farrelly  3 , Shrinkhala Dawadi  3 , Allan Hackshaw  3 , Anand Devaraj  4 , Arjun Nair  2 , Sam M Janes  5 ; SUMMIT Consortium
Affiliations
Observational Study

Stage at Diagnosis Following Delay to Interval Scans for Indeterminate Nodules in Lung Cancer Screening: An Observational Study Examining the Outcomes of CHEST Expert Panel Recommendations

Andrew W Creamer et al. Chest. 2024 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Financial/Nonfinancial Disclosures The authors have reported to CHEST the following: A. W. C., C. H., J. L. D., S. T., H. H., P. V., R. P., A. B., and C. R. K. are all funded or part-funded through GRAIL as part of the SUMMIT Study. SUMMIT is sponsored and conducted by University College London and funded by GRAIL LLC through a research grant awarded to S. M. J. as principal investigator. S. M. J. is a paid Advisory Board member Astra-Zeneca, Bard1 Bioscience, Achilles Therapeutics, and Jansen; receives assistance for travel to meetings from Astra Zeneca, Takeda; receives grant income from GRAIL Inc, Owlstone; and receives share options from Optellum and BARD1 Lifescience. A. N. is part-funded through the UCLH Biomedical Research Centre. A. D. receives personal fees from Boehringer Ingelheim, Roche, Galacto Biotech, Galapagos, Brainomix and Vicore. A. H. receives consulting fees from Evidera and assistance for travel to meetings from GRAIL. None declared (J. M., T. L., K. G., A.-M. H., J. T., L. F., S. D.).

References

    1. Mazzone P.J., Gould M., Arenberg D., et al. Management of lung nodules and lung cancer screening during the COVID-19 pandemic: CHEST Expert Panel Report. Chest. 2020;158(1):406–415. - PMC - PubMed
    1. WHO Director-General’s opening remarks at the media briefing. https://www.who.int/news-room/speeches/item/who-director-general-s-openi... 5 May 2023.
    1. Rivera M.P., Durham D.D., Long J.M., et al. Receipt of recommended follow-up care after a positive lung cancer screening examination. JAMA Netw Open. 2022;5(11) e2240403. - PMC - PubMed
    1. National Institutes of Health Clinical Center . National Institutes of Health; 2019. The SUMMIT study: A cancer screening study (SUMMIT). NCT03934866. ClinicalTrials.gov.https://classic.clinicaltrials.gov/ct2/show/NCT03934866 Updated November 29, 2023.
    1. Horst C., Dickson J.L., Tisi S., et al. Delivering low-dose CT screening for lung cancer: a pragmatic approach. Thorax. 2000;75(10):831–832. - PubMed